Liquid Biopsy Market Size is expected to develop at a compound annual growth rate (CAGR) of 24.5% from 2025 to 2035
The liquid biopsy market was estimated to be worth USD 6.1
billion globally in 2024, and a compound annual growth rate (CAGR) of 24.5% is
anticipated throughout the course of the projected period. The market for
liquid biopsies is expanding due to the growing number of non-invasive
procedures and the increased incidence and prevalence of cancer. The market is
expanding significantly due to rising demand for disease monitoring and growing
public awareness of the treatment of chronic illnesses.
A liquid biopsy
is easier to use and more convenient than a standard biopsy. It encompasses
many technologies, like circulating tumor DNA analysis and circulating tumor
cells. The market is expanding as a result of less invasive testing, early
cancer detection, and individualized medication.
Request For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/liquid-biopsy-market
Growth
Drivers
The demand in
the liquid biopsy market is being driven by the growing number of patients with
carcinoma worldwide and the growing popularity of less invasive procedures
among people. Government campaigns to raise awareness of cancer are a major
factor in the market's growth. Increasing need for less invasive alternatives
to standard tissue biopsies, which are quite painful and contain hazards, is
making this approach more tempting and convenient.
Liquid biopsies
do offer sensitive diagnostic techniques for early detection and monitoring,
which are becoming more and more necessary due to the rising incidence of
cancer worldwide. Adoption rates are anticipated to rise among healthcare
organizations and clinicians as more clinical data shows how useful liquid
biopsies are in directing treatment choices and enhancing patient outcomes. The
accuracy and dependability of liquid biopsy tests have increased due to developments in microfluidics,
sequencing technology, and other analytical methods, which has fueled market
expansion.
Segmentation
By
Product and Services
· Assay
Kits
· Instruments
· Services
By
Application
· Cancer
· Lung
Cancer
· Breast
Cancer
· Colorectal
Cancer
· Prostate
Cancer
· Melanoma
· Other
Cancers
· Non-Cancer
applications
· Non-Invasive
Pre-Natal Testing
· Organ
Transplantation
· Infectious
Disease Testing
By Sample
Type
· Blood
· Other
Sample Types
Regional
Outlook
· Asia
Pacific
· North
America
· Latin
America
· Europe
· Middle
East and Africa
Key
Players
· Thermo
Fisher Scientific Inc
· Myriad
Genetic Inc
· Guardant
Health Inc
· Qiagen
N.V.
· F.
Hoffman La Roche Ltd.
· ANGLE
Plc
· Biocept
Inc
· Lucence
Health Inc
· Freename,
Holdings Inc
· Oncimmune
Holdings Plc
· Other
Players
For More Information about this Report @
https://www.xresearch.biz/shop/liquid-biopsy-market
About Us: -
xResearch is a market research and consulting
organization that uses unique data, expert analysis, and new technologies to
create trusted intelligence on industries. Our research is focused on
delivering an informed and impartial view on essential market data of industry,
and it is primarily driven by an in-depth study covering the following
parameters: Market Sizing and Forecasting, Market Segmentation, Competitive
Analysis, Strategic Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Websites: https://www.xresearch.biz/

Comments
Post a Comment